Featured Research

from universities, journals, and other organizations

Selectively stopping glutathione sensitizes brain tumors to chemotherapy

Date:
January 12, 2012
Source:
University of Colorado Denver
Summary:
Brain cancer cells are especially resistant to chemotherapy -- new research details the mechanism of this resistance and provides a powerful strategy for countering it.

Brain cancer cells are particularly resistant to chemotherapy -- toxins enter the cells, but before the toxins can kill, cancer cells quickly pump them back outside. In fact, brain cancer cells are even better than healthy cells at cleaning themselves. This means that when hit with chemotherapy, healthy cells tend to die before brain cancer cells. Especially in the brain, killing healthy cells is bad.

Researchers at the University of Colorado Cancer Center have discovered a way to turn off the pumps -- only in brain cancer cells and not in their healthy neighbors. Promising early testing provides hope for the nearly 45,000 people diagnosed with brain cancer in the United States every year, who are currently expected to survive less than 12 months after diagnosis.

The key is a chemical called glutathione (GSH).

The GSH pathway allows both healthy and cancerous cells to pump out toxins. The more GSH a cell makes, the more efficiently it can cleanse itself. Brain cancer cells may literally coat themselves with GSH, allowing them to pump out and thus survive doses of chemotherapy that quickly kill healthy brain cells.

This GSH pathway is the focus of a recent CU Cancer Center paper published in the journal Biochemical Pharmacology.

But this same mechanism that makes brain cancer cells especially hearty may in fact be the key to their demise.

The idea is this: stop a cell's ability to make GSH and you stop its ability to detoxify -- thus sensitizing the cell to even a low dose of chemotherapy. It's tricky to target GSH directly, but clinical trials are already underway for a drug that breaks a link in the chain that leads to GSH. The link is an enzyme called glutamate cysteine ligase (GCL), which cells need in order to make GSH.

No GCL means no GSH, means a cell is doomed to stew in chemotherapy rather than pumping it out.

Unfortunately, the drug in clinical trials stops ALL cells -- healthy and cancerous -- from making GSH. And by so doing, it sensitizes both healthy and cancerous cells to chemotherapy. Killing everything more effectively does little good. (The same could be accomplished simply by giving a higher dose of chemotherapy.)

So here is the trick and the promise: "If we can selectively keep brain tumor cells from making GSH we can sensitize these tumors to chemotherapy, which may allow doctors to kill more tumor cells with a safe dose of chemotherapeutics," says Christopher Franklin, PhD, investigator at the CU Cancer Center and assistant professor of molecular toxicology at the Skaggs School of Pharmacy and Pharmaceutical Sciences.

Franklin is working with Philip Reigan, PhD, investigator at the CU Cancer Center and assistant professor of medicinal chemistry at the Skaggs School of Pharmacy and Pharmaceutical Sciences to do just that -- targeting cancer cells' GSH while leaving the pathway unharmed in healthy cells.

To do it, they're using an exciting class of medicines called prodrugs. By itself a prodrug doesn't do anything -- it floats harmlessly through the body. Only, when it comes in contact with another target chemical the prodrug releases a little payload.

In this case, the prodrug payload is the drug that stops cells from making GSH. And the chemical that tells the prodrug to release its payload is an enzyme specific to brain cancer cells. This means that only when near brain cancer cells does the prodrug stop cells' ability to make GSH. Given along with chemotherapy, the prodrug should turn the table on brain cancer cells, making them die sooner than healthy neighbors.

"The current standard of care adds only about three months to the life expectancy of a patient diagnosed with glioblastoma multiforme," Reigan says. "The promise of prodrugs that selectively target tumor cells is not only exciting, but it's desperately needed for the treatment of brain tumors."


Story Source:

The above story is based on materials provided by University of Colorado Denver. Note: Materials may be edited for content and length.


Journal Reference:

  1. Donald S. Backos, Christopher C. Franklin, Philip Reigan. The role of glutathione in brain tumor drug resistance. Biochemical Pharmacology, 2011; DOI: 10.1016/j.bcp.2011.11.016

Cite This Page:

University of Colorado Denver. "Selectively stopping glutathione sensitizes brain tumors to chemotherapy." ScienceDaily. ScienceDaily, 12 January 2012. <www.sciencedaily.com/releases/2012/01/120112095857.htm>.
University of Colorado Denver. (2012, January 12). Selectively stopping glutathione sensitizes brain tumors to chemotherapy. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/01/120112095857.htm
University of Colorado Denver. "Selectively stopping glutathione sensitizes brain tumors to chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2012/01/120112095857.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins